Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.
about
Phosphate binders for preventing and treating bone disease in chronic kidney disease patientsChronic kidney disease mineral and bone disorder in childrenJuice powder concentrate and systemic blood pressure, progression of coronary artery calcium and antioxidant status in hypertensive subjects: a pilot studyHyperphosphatemia Management in Patients with Chronic Kidney DiseaseCurrent understanding of coronary artery calcificationPre-treatment considerations in childhood hypertension due to chronic kidney diseaseMechanisms of arterial calcifications and consequences for cardiovascular functionThe role of phosphorus in the development and progression of vascular calcificationArterial calcification in chronic kidney disease: key roles for calcium and phosphatePharmacologic management of chronic reno-cardiac syndromeHyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherenceRecent advances in the management of hemodialysis patients: a focus on cardiovascular diseaseManagement of hyperphosphataemia in chronic kidney disease: summary of National Institute for Health and Clinical Excellence (NICE) guidelineAre there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patientsLanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherenceArterial stiffness, vascular calcification and bone metabolism in chronic kidney diseasePhosphate control in dialysisCalcium and phosphate impact cardiovascular risk.Practical use of sevelamer in chronic kidney disease patients on dialysis in People's Republic of China.Vascular calcification: When should we interfere in chronic kidney disease patients and how?Calciphylaxis--a topical overviewTotal and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patientsOutcomes associated with serum calcium level in men with non-dialysis-dependent chronic kidney diseaseCarotid artery calcification at the initiation of hemodialysis is a risk factor for cardiovascular events in patients with end-stage renal disease: a cohort study.Fetuin-A and kidney function in persons with coronary artery disease--data from the Heart and Soul Study.Association of kidney function and uncarboxylated matrix Gla protein: data from the Heart and Soul Study.Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis.Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.End stage renal disease.Pharmacotherapy of end-stage renal disease.Longitudinal relationships among coronary artery calcification, serum phosphorus, and kidney function.Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin.Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification.Phosphate and cardiovascular diseaseThe emerging role of phosphate in vascular calcification.Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients.Risk factors of one year increment of coronary calcifications and survival in hemodialysis patientsEvaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
P2860
Q24234036-2D5A75E2-9524-4F16-97A5-B71E1F698580Q24642788-D6C07A8A-8934-4DA1-AA62-D8521DBCFF5FQ24685582-376BAFA6-9A64-40ED-953E-732D20D30BC3Q26743842-6FABC8E4-607D-402B-A73D-2EC120D86222Q26770851-91825DC6-6B6F-498D-8246-F3F12C1E1D0CQ26777613-12BE6867-A16B-4C44-AC15-C6246C92F89AQ26821993-33718F27-3725-4D49-916F-2691228528CFQ26823897-330DD46B-2525-439C-B4E9-8DEB672FF52AQ26827655-81723E94-5D92-4A59-88A7-6F1B5E6E6B67Q26829812-286EA6C9-E08C-4F44-856B-BB1BEC3E4385Q26830013-14944E7B-11A1-461E-B3CB-9C63CD2F4A90Q26849298-64C579F5-9A80-4938-99A3-D933959FFA06Q26866391-9BE0BBA7-B947-436A-BBBD-7FD431773D1CQ27002431-B4773745-558F-40FD-9870-DBFBD45250B8Q27006968-C3AAA0F3-B1F7-4A42-AF0E-6EF921F65A1EQ27013882-2014698C-2B79-4BA9-AE12-6AC182310B38Q27024623-89FE4E4C-1CB6-45A4-86AE-70D965D3EB97Q27025339-57E7ACA3-25FE-4E03-A598-3A92EB027411Q27687570-5CA3EBE3-356D-4BA9-90CD-4411E55EBF4AQ27691991-40A93C84-D0FD-4180-9C89-50860928C925Q28071582-017DBB15-9507-4BFF-8331-5E823D43D98DQ28239109-C74466AA-1BAF-415B-BBE1-E4721B3381FAQ30432443-1AE41C5A-9D7C-4378-A276-E5E04EF5ADF0Q30433029-08468AC0-CB89-433F-986A-329119C6BB95Q30473207-CCF99920-8495-4771-B332-A10968F71068Q31038421-5F456CD6-F9DE-47F6-80FF-9B0DDA401D0DQ33407103-3765520B-AF76-4B8B-A1AA-9370257E5B5FQ33410839-07E0FA47-CC78-44B4-AA81-DAC778CE4608Q33432770-0DF7A9E7-A5CB-42AF-B447-BE3E59CC3D9CQ33446829-47B62789-AA33-4952-9A5E-5B32FAF1F2B5Q33531889-D193F8F2-83F0-45E7-8E7D-BF6DF0DA893EQ33560460-5AAD11C3-B0F8-4CF0-A6B7-530A8994B4C9Q33562017-B106E313-9DB3-40DF-9B14-9833F8ED64BEQ33562186-D85C7755-6F54-45BD-80D2-41EBAFBDF12DQ33566596-6904367F-3202-44DA-B472-247AEF76B8B6Q33595584-D91ED430-29F2-4036-88B3-6A762B0921B1Q33610289-52DD4E00-60BB-428F-B303-FC4ECE794FD5Q33610457-5D9924D6-635F-41EF-B9DA-193C3B33521AQ33611410-31BCAC2D-C11A-44E5-81CF-D3B14A4626BCQ33615078-CA1B8B9D-935B-4921-AEEE-67D5E30AA1CC
P2860
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Sevelamer attenuates the progr ...... tion in hemodialysis patients.
@en
Sevelamer attenuates the progr ...... tion in hemodialysis patients.
@nl
type
label
Sevelamer attenuates the progr ...... tion in hemodialysis patients.
@en
Sevelamer attenuates the progr ...... tion in hemodialysis patients.
@nl
prefLabel
Sevelamer attenuates the progr ...... tion in hemodialysis patients.
@en
Sevelamer attenuates the progr ...... tion in hemodialysis patients.
@nl
P2093
P1433
P1476
Sevelamer attenuates the progr ...... tion in hemodialysis patients.
@en
P2093
Glenn M Chertow
Paolo Raggi
Steven K Burke
Treat to Goal Working Group
P304
P356
10.1046/J.1523-1755.2002.00434.X
P407
P577
2002-07-01T00:00:00Z
P5875
P6179
1049735389